Shankar Siva
@_ShankarSiva
Followers
9K
Following
16K
Statuses
6K
Radiation Oncologist at the Peter MacCallum Cancer Centre @petermaccc, Professor of Medicine, University of Melbourne, Australia 🇦🇺. Views are my own. #radonc
Melbourne, Victoria
Joined July 2012
1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now @LancetRespirMed - Led by 🫁@DanSteinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc @tssmn @PeterMacRadOnc
9
93
225
RT @David__Pasquier: Glad to have co-led this multicenter SBRT series for primary kidney cancer with @_ShankarSiva 144 patients, making it…
0
3
0
RT @nbn426: Important patients know whether it is kidney or liver SBRT triumphs at local control for tumors of intermediate size ( greater…
0
3
0
RT @alongi_filippo: -This large series of primary RCC treated with SBRT demonstrates excellent LC and renal function preservation. -SBRT i…
0
14
0
RT @CiroFranzese1: Joining forces against kidney cancer! Published a new international multicenter study on SBRT for renal cell carcinoma…
0
10
0
RT @DrAndrewLoblaw: All these data tell the same story: #SBRT should be the preferred treatment for larger tumours for medically inoperable…
0
6
0
📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc
2
87
180
@crispinhiley @gerryhanna @ClinOncologist @JCO_ASCO @fifimcdrmh @DrewMoghanaki @finn_corinne @gwalls89 @DavidDbal @cpeedell @Mat_Guc @DrJNaidoo @FordePatrick @drdavidpalma @HoudaBahig @bensolomon1 But why would this data be invalid with a different TKI? Generally as systemic therapy improves the importance of local therapy for macroscopic disease becomes more important? TKI are not curative.
2
0
8
@gerryhanna @ClinOncologist @JCO_ASCO @fifimcdrmh @DrewMoghanaki @finn_corinne @gwalls89 @DavidDbal @cpeedell @Mat_Guc @DrJNaidoo @FordePatrick Good to see it’s possible to PRIME-lung in the EGFR-TKI setting! @DrJNaidoo @gerryhanna @drdavidpalma @HoudaBahig @bensolomon1
1
0
5
RT @DrDanielHeng: @_ShankarSiva @DrChoueiri @AlbigesL @DrRanaMcKay @tompowles1 @DrewMoghanaki @ChadTangMD Totally agree SABR is an importan…
0
2
0
👀⬇️ @HwakeleeMD @finn_corinne @TommyJohn00 @StephenVLiu @VamsiVelcheti @DrAlexLouie @HendriksLizza @AndrearicFili @pablomunozsch @fifimcdrmh @DrSanjayPopat @IASLC
Interesting paper just out in @JCO_ASCO Chinese study in patients with EGFR positive oligo-organ metastatic #NSCLC. TKI plus RT group received 60Gy to primary and positive LNs. RT to metastases determined by clinicians. Median OS was 26.2 months and 34.4 months (RT)
0
4
17
RT @cristian_udo: Is there a potential role for prostate SBRT < 5 fractions? Great to share our @EurUrolOncol TOFFEE meta-analysis compar…
0
12
0
TFS (treatment breaks) at 1-year is ~90% with SABR; for selected patients this might be the optimal choice! 1) 2) 3) #radonc @DrChoueiri @AlbigesL @DrRanaMcKay @tompowles1 @DrewMoghanaki @ChadTangMD
Treatment free survival is becoming an important endpoint when looking at different #mRCC treatments. VEGF alone had shortest TFS. Something to be said about treatment breaks. Thx to #mehulgupta and #meredithregan @IMDConline @DrRanaMcKay @tompowles1 @DrChoueiri @EurUrolOncol
1
19
44
⬇️ Worth remembering #radonc !
When you’re constantly reviewing radiotherapy isodose distributions on large computer screens it’s easy to lose sight of just how amazingly accurate linacs are. We can deliver ablative doses of radiation with mm accuracy! Here are a list of other things that are 1 mm in size
2
8
46
@DrJNaidoo @gerryhanna @IrishLungCancer @CancerInstIRE @IRROGTrials @FordePatrick @PeterMacCC @IASLC @QUBelfast @ProfJohnKennedy @finn_corinne @gwalls89 @fifimcdrmh @cancertrials_ie Congrats @gerryhanna !!! Looking sharp!
0
0
4
RT @DrJNaidoo: Congrats to @gerryhanna on his Inaugural lecture as Marie Curie Chair of Radiation Oncology🇮🇪 An inspiring talk from a phy…
0
8
0
RT @oncology_bg: These last 2 months have been our milestone months. We have published some- in my opinion- really important pieces. Since…
0
11
0
RT @DrYukselUrun: 🎉 Exciting News! Proud to share our latest research on the impact of comorbidities on survival in cancer patients receiv…
0
37
0
RT @oncology_bg: Ever wondered why the results of 3 immunotherapy trials in urothelial cancers are different? Is it truly because the 3 dru…
0
25
0
RT @CZamboglou: Excited to share two major milestones of our global Co-IMPACT project: ➡️Homepage is live: ➡️New pa…
0
16
0